US moves to sell gene-edited mushrooms fuel doubts over British ban on GM imports
By Robin McKie,
The Guardian
| 04. 23. 2016
Untitled Document
American regulators have allowed the cultivation and sale of two crops modified with the gene-editing technique known as Crispr. The crops – a white button mushroom and a form of corn – are the first Crispr plants to be permitted for commercial use in the US.
The move is a boost for new technology in the creation of foodstuffs, but is expected to worsen the considerable confusion in Britain over the use of gene-editing in agriculture and the importing of crops created using such technology.
A committee of European commission regulators was expected to report last month on whether gene-edited crops should be classed as genetically-modified organisms or should be freed from the severe restrictions concerning GMOs in Europe. At the last minute it announced a delay in its verdict – to the dismay of many UK scientists.
“The committee knew it would be highly controversial, no matter what decision it made, so they have kicked the issue into the long grass, and that is very damaging,” said crop scientist Professor Huw Jones of Aberystwyth university.
“Researchers...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...